

EXHIBIT B

Loss Chart

Losses of Susan S. Church in Cocystal Pharma, Inc. f/k/a/ BioZone Pharmaceuticals, Inc.
(COCP)

Client Name Susan S. Church
Cocrystal Pharma, Inc. f/k/a/
Company Name BioZone Pharmaceuticals, Inc.
Ticker Symbol COCP
Class Period Start 9/23/2013
Class Period End 9/7/2018

90 Day Lookback Average \$2.4910

LIFO Loss Total \$52,204.61
Dura LIFO Total \$52,204.61
Shares Retained 4,333

<u>Acquisition Date</u>	<u>Quantity of Securities Purchased</u>	<u>Quantity of Securities Adjusted</u>	<u>Price Per Security</u>	<u>Price Per Security Adjusted</u>	<u>Total Cost</u>	<u>Disposition Date</u>	<u>Securities Sold</u>	<u>Actual Sales Price Per Security</u>	<u>Avg. Trading Price on Date of Sale*</u>	<u>Total Proceeds from Sale</u>	<u>Securities Held at Close of Class Period</u>	<u>Per Security Value</u>	<u>Retained Value</u>	<u>Total Proceeds/Loss (LIFO)</u>	<u>Dura LIFO**</u>
10/1/2013	80,000	2,666.67	\$0.5600	\$16.80	\$44,800.0000					\$0.0000	2,666.67	2.491	\$ 6,642.67	\$38,157.33	\$38,157.33
10/2/2013	20,000	666.67	\$0.5000	\$15.00	\$10,000.0000					\$0.0000	666.67	2.491	\$ 1,660.67	\$8,339.33	\$8,339.33
10/4/2013	8,000	266.67	\$0.4750	\$14.25	\$3,800.0000					\$0.0000	266.67	2.491	\$ 664.27	\$3,135.73	\$3,135.73
6/1/2017	10,000	333.33	\$0.2000	\$6.00	\$2,000.0000					\$0.0000	333.33	2.491	\$ 830.33	\$1,169.67	\$1,169.67
6/1/2017	1,800	60.00	\$0.2000	\$6.00	\$360.0000					\$0.0000	60.00	2.491	\$ 149.46	\$210.54	\$210.54
6/1/2017	5,200	173.33	\$0.1971	\$5.91	\$1,024.9200					\$0.0000	173.33	2.491	\$ 431.77	\$593.15	\$593.15
6/2/2017	1,000	33.33	\$0.2000	\$6.00	\$200.0000					\$0.0000	33.33	2.491	\$ 83.03	\$116.97	\$116.97
6/2/2017	4,000	133.33	\$0.2047	\$6.14	\$818.8000	1/29/2018***	0.33	\$16.9697		\$5.6000	133.00	2.491	\$ 331.31	\$481.89	\$481.89
TOTAL:	130,000	4,333.33			\$63,003.72		-			\$5.60	4,333.00		\$ 10,793.51	\$52,204.61	\$52,204.61

* Post-class period sales valued using the greater of: (1) the average closing price between the end of the class period and the sales date; or (2) the actual sales price.

** Disregarding intra-class period gains and losses.

*** Forced sale due to holding of fractional share.